The following is true of anti-H. pylori therapy EXCEPT:
Triple drug therapy for H. pylori is indicated in those patients in whom infection is detected by urea breath test. Since H. pylori becomes less virulent in the absence of acid, combination with PPI is more effective. Because resistance can develop to single agents, these are used in combination. Colloidal bismuth subcitrate dislodges H. pylori but produces metallic taste and blackening of tongue.
It is indicated in all patients of peptic ulcer
Resistance to any single antimicrobial drug develops rapidly
Concurrent suppression of gastric acid enhances the efficacy of the regimen
Colloidal bismuth directly inhibits H. pylori but has poor patient Acceptability
Kidney, Respiratory, GIT and Autacoids